A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2019-07-17
Target enrollment:
Participant gender:
Summary
This study tests the safety of a drug called SGN-CD352A, to find out what its side effects
are. SGN-CD352A will be given every 4 weeks to a small group of patients with multiple
myeloma.